Payment overview · 2025
General Payments
$310.12
17 reported records · 7 companies
Healthcare provider profile · identity verified
Paul Krisa, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WOODLAND PARK, NJ · NPI 1588608525
Verified facts
What the public records show
CMS Open Payments records show Paul Krisa, MD received $310.12 in general payments during 2025 across 17 reported records.
ABBVIE INC. accounted for 32.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $100.47 | 32.4% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $80.06 | 25.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.25 | 12.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.95 | 10.6% | 2 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $23.54 | 7.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.74 | 6.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.11 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $310.12 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $84.93 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $84.93 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $80.06 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $39.25 | 2 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 524 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 292 | 91 |
| Losartan Potassium | Losartan Potassium | 225 | 56 |
| Eliquis | Apixaban | 213 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 177 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 175 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 170 | 55 |
| Mirtazapine | Mirtazapine | 159 | 23 |
| Gabapentin | Gabapentin | 157 | 40 |
| Famotidine | Famotidine | 149 | 47 |
| Furosemide | Furosemide | 148 | 40 |
| Donepezil Hcl | Donepezil Hcl | 144 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 127 | 52 |
| Metformin Hcl | Metformin Hcl | 126 | 34 |
| Simvastatin | Simvastatin | 106 | 27 |
| Carvedilol | Carvedilol | 105 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 98 | 34 |
| Levetiracetam | Levetiracetam | 98 | 18 |
| Montelukast Sodium | Montelukast Sodium | 96 | 33 |
| Potassium Chloride | Potassium Chloride | 91 | 22 |
| Sertraline Hcl | Sertraline Hcl | 86 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 28 |
| Lisinopril | Lisinopril | 82 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 22 |
| Meloxicam | Meloxicam | 79 | 23 |
| Divalproex Sodium | Divalproex Sodium | 68 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 17 |
| Omeprazole | Omeprazole | 68 | 22 |
| Farxiga | Dapagliflozin Propanediol | 67 | 12 |
| Januvia | Sitagliptin Phosphate | 59 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 16 |
| Allopurinol | Allopurinol | 50 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 50 | 16 |
| Albuterol Sulfate | Albuterol Sulfate | 48 | suppressed |
| Baclofen | Baclofen | 48 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 18 |
| Memantine Hcl | Memantine Hcl | 47 | 15 |
| Risperidone | Risperidone | 46 | suppressed |
| Azithromycin | Azithromycin | 45 | 31 |
| Finasteride | Finasteride | 45 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 13 |
| Valsartan | Valsartan | 43 | 13 |
| Glipizide | Glipizide | 38 | 13 |
| Jardiance | Empagliflozin | 38 | 13 |
| Lactulose | Lactulose | 38 | suppressed |
| Olanzapine | Olanzapine | 38 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 37 | 22 |
| Cefuroxime | Cefuroxime Axetil | 37 | 29 |
| Prednisone | Prednisone | 35 | suppressed |
| Ezetimibe | Ezetimibe | 34 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | 13 |
| Torsemide | Torsemide | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | 17 |
| Atenolol | Atenolol | 31 | suppressed |
| Latanoprost | Latanoprost | 31 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 31 | 12 |
| Spironolactone | Spironolactone | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 23 |
| Ramipril | Ramipril | 28 | suppressed |
| Vascepa | Icosapent Ethyl | 28 | 12 |
| Brilinta | Ticagrelor | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 16 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 26 | suppressed |
| Austedo | Deutetrabenazine | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Olanzapine Odt | Olanzapine | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 20 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 19 | 11 |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 18 | 12 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Budesonide | Budesonide | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 11 |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Cyclosporine | Cyclosporine | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Sodium Bicarbonate | Sodium Bicarbonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $310.12 · 17 records | ABBVIE INC. | CAPLYTA, Cologuard Collection Kit, FFRct, GEMTESA, QULIPTA, SHINGRIX, UBRELVY, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error